Issues addressed by tuberculosis in France in 2003;Quels sont les problèmes posés par la tuberculose en France en 2003?

Medecine/Sciences

Volumn 19, Issue 11, 2003, Pages 1146-1151

  Bouvet, Élisabeth ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

BACTERIAL INFECTION; BCG VACCINATION; DISEASE TRANSMISSION; FRANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; INFECTION CONTROL; INFECTION RATE; MULTIDRUG RESISTANCE; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM BOVIS BCG;

EID: 0242666069     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200319111146     Document Type: Review

References (18)

1. Schwoebel V, Hubert B, Desenclos JE. Investigations à conduire autour d'un cas de tuberculose ou de primo-infection tuberculeuse récente. BEH 1994; 9: 39-42.
2. Styblo K. Recent advances in epidemiological research in tuberculosis. Adv Tuberc Res 1980; 20: 1-63.
3. Van Soolingen D. Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements. J Intern Med 2001; 249: 1-26.
4. Geng E, Kreiswirth B, Driver C, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002; 346: 1453-8.
5. INVS (Institut de veille sanitaire). Impact épidé miologique d'une modification de la politique de vaccination par le BCG en France. Revue de la littérature et analyse des données disponibles. Saint-Maurice: INVS, 2001.
6. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobactrium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999; 353: 444-9.
7. Decludt B, Campese C. Les cas de tuberculose déclarés en France en 2000. BEH 2002; 16-17: 68-70.
8. Infuso A, Antoine D, Barboza P, Euro TB. Surveillance européenne de la tuberculose en 1999 et tendances récentes. BEH 2002; 16-17: 66-7.
9. WHO (World health organization). Antituberculosis drug resistance in the world. Report n°2. Prevalence and trends. Genève: WHO, 2000.
10. CDC (Centers for disease control and prevention). Epidemiologic notes and reports. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons, Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep 1991; 40: 585-91.
11. Robert J, Trystram D, Truffot-Pernot C, Jarlier V. Surveillance de la tuberculose à bacilles multirésistants en France en 1998. BEH 2002; 16-17: 73-6.
12. Schluger NW, Ram WN. The host immune response to tuberculosis. Am J Respir Crit Care Med 1998; 157: 679-91.
13. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA 1999; 282: 677-86.
14. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-64.
15. INVS (Institut de veille sanitaire). Surveillance du SIDA en France. Situation au 31 mars 2002. BEH 2002; 27: 133-8.
16. CDC (Centers for disease control and prevention). Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000; 49: RR-6.
17. Gordin FM, Chaisson RE, Matts JP, et al. An international randomized trial of rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons. JAMA 2000; 283: 1445-50.
18. Bailey WC, Gerald LB, Kimerling ME, et al. Predictive model to identify positive tuberculosis skin test results during contact investigations. JAMA 2002; 287: 996-1002.